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ABSTRACT 
 Cocaine is one of the most common drugs of abuse in the United States 
today, but street-quality cocaine is decreasing in purity each year.  This change in 
purity requires a shift in the focus of cocaine analysis in forensic laboratories.  In 
recent years, many federal agencies have begun testing and profiling for the 
adulterants and diluents present in cocaine samples submitted as evidence.  By 
analyzing the compounds present in the street-quality samples, forensic chemists 
may be able to track the cocaine back to its source, based on the unique identities 
of certain adulterants. 
 Many of the adulterants currently being added to cocaine are dangerous 
on their own, even though they may enhance the effects of the cocaine.  For this 
reason many doctors and forensic pathologists are interested in the identities of 
the adulterants present.  Often times, a sample of the cocaine ingested may not 
be available for testing.  Thus, there is a need for the development of methods to 
test for these adulterants and their metabolites in biological samples. 
 The objective of this research is to develop extraction and instrumental 
analysis methods for several common cocaine adulterant metabolites, in an effort 
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to create a geographical profile of human urine samples that tested positive for 
benzoylecgonine, a cocaine metabolite, and exploring the possible trends.
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Introduction 
Cocaine 
 Cocaine is an alkaloid, utilized as an anesthetic and originating from 
Erythroxylum coca (E. coca) and Erythroxylum novogranatense (E. 
novogranatense), both of which are shrubs grown primarily in regions of South 
America.  While the alkaloid cocaine can be extracted from both of these species 
of plants, it is more highly concentrated in E. coca, and therefore is harvested 
primarily from this species (1).  The leaves from these shrubs have a history of 
being brewed into teas or chewed by locals for energy as well as an increased 
sense of well being and awareness.  For many years, cocaine was used as an 
anesthetic in medicine in the United States for eye, ear, nose, and throat surgery, 
and continues to be a Schedule II drug today, which means it is classified as 
having a high potential for abuse but still has legitimate medical uses (2).   
 Cocaine acts in two ways on the body.  Its first and foremost action is to 
stimulate the sympathetic nervous system, which controls involuntary actions 
such as heart rate and blood pressure.  It performs this action on the sympathetic 
nervous system by blocking the reuptake of certain neurotransmitters in a 
synapse.  This results in a higher concentration of neurotransmitters, in this case 
dopamine, epinephrine/norepinephrine, and serotonin, in the synapse making 
them available for stimulation of the post-synaptic cleft receptors (3).  Cocaine 
also acts as a topical anesthetic and is known to be the only topical anesthetic to 
also constrict blood vessels, making it the preferred anesthetic used to perform 
eye surgery (2).  Cocaine acts as an anesthetic by blocking sodium channels in 
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cells, thus making it more difficult for impulses to travel from nerve to nerve, 
ultimately slowing them down (1). 
 The results of this pharmacological action, in smaller doses, is a sense of 
euphoria, higher energy levels, and more mental awareness to certain sensations 
such as sight, sound, and touch (5).  As far as long-term effects are concerned, 
cocaine is one of the more addicting illicit drugs in its high occurrence of relapse 
even after certain periods of abstinence.  As with many other drugs, the user can 
develop a tolerance to the drug, and thus need an increasing dose to actually 
obtain the same feelings they experienced previously.  Other specific long-term 
effects depend on the route of administration; for example, snorting cocaine can 
lead to damaged nasal passages while injecting it can lead to damaged blood 
vessels.  Overall, chronic cocaine use can lead to the following health 
complications: tremors, convulsions, hallucinations, loss of appetite and 
eventually malnourishment, insomnia, stroke, cardiac arrest, and even death (5). 
 Cocaine, as known by a layperson, is not found naturally in the world but 
is extracted or removed from the plant material itself before being sent around 
the world.  This extraction process is often times performed in the jungles where 
the plant is harvested.  The leaves are sprinkled with an alkaline material such as 
cement or lime and a strong solvent such as kerosene or gasoline is added.  The 
leaves are compressed by stomping to encourage the removal of cocaine from the 
leaves.  The leaves and water are drained off and discarded, often times into local 
streams.  The resulting solution is extracted with dilute sulfuric acid in a solvent 
and sodium carbonate.  The resulting precipitate is cocaine sulfate, also known as 
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cocaine paste.  The cocaine paste is further extracted to result in cocaine base and 
then cocaine hydrochloride (HCl).  Several active and inactive ingredients are 
then added to the cocaine HCl, to make it less pure, a process known as “cutting” 
the product (6).  
 This process can be performed with simple ingredients such as sugar, 
baking soda or baby powder to add to the bulk of the drug, or with other drugs 
such as lidocaine, benzocaine, caffeine, and others to enhance the effect of the 
cocaine (7).  While these drugs enhance the effect, they can also make the drug 
more appealing to purchase.  Often times, a buyer will place some of the product 
on the inside of their lip to test out the anesthetic abilities of the product.  While 
cocaine is an anesthetic, procaine, lidocaine, and benzocaine also act as numbing 
agents; therefore, the buyer gets the impression that they are purchasing a 
“good” product, when in actuality it is dilute (8). The innocuous additives are 
known as diluents and the enhancing substances are known as adulterants.  
Oftentimes, the mixed substances are added as a marker to that particular 
“brand” of cocaine (9). These adulterants and diluents, while seemingly harmless 
on their own, can actually cause many health issues to their consumer who may 
be completely unaware of their presence in street quality cocaine.  Many users 
have become very ill or even died due to the harmful effect of an additive in their 
cocaine.   
 Cocaine is administered through four principle routes: orally, intranasally 
or snorting, intravenously and inhalation.  All of these routes of administration 
are dangerous and can result in over-absorption of toxic levels of cocaine, 
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depending on many factors, including but not limited to the purity of the sample.  
In a summary from 2007, the National Institute on Drug Abuse (NIDA) reported 
that prices of street cocaine are increasing while the purity has dropped to nearly 
50% (3).  The National Forensic Laboratory Information System report from 2011 
provided data from three different reporting laboratories for cocaine purity.  In 
two of the three laboratories, the purity followed this trend, with purity 
dropping to approximately 52-56% in recent years (4).  For this reason, it is 
becoming increasingly important that the other constituents of street cocaine 
samples are identified.  The Drug Enforcement Agency (DEA) has been profiling 
cocaine for their diluents and adulterants since 1997 in a program known as the 
Cocaine Signature Program (CSP).  This program takes samples from over 2000 
bulk seizures of cocaine from across the United States of America (USA) every 
year.  By inventorying cocaine samples for specific adulterants and diluents and 
their combinations, solvents used in extraction, and for the isotopic differences in 
the cocaine itself from region to region, agencies may draw conclusions about 
similarities between certain batches of illicit drugs and try to narrow down their 
sources (10).  These strategies and studies are becoming increasingly important 
due to the rising popularity of cocaine.  For example, the Drug Abuse Warning 
Network (DAWN) data from August 2008 shows that the most commonly 
reported illegal drug in hospital emergency rooms is cocaine; approximately 1 in 
3 reports involve cocaine (5). 
 The Scientific Working Group for the Analysis of Seized Drugs 
(SWGDRUG) provides a guideline of recommendations for sampling, storing, 
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and testing of seized illicit drugs.  SWGDRUG recommends that a combination 
of the following categories of evaluation be used to test seized samples, and the 
suggested analyses of cocaine are italicized and boldfaced (11). 
Table 1- SWGDRUG Recommendations 
Category A Category B Category C 
Infrared Spectroscopy Capillary Electrophoresis Color Tests 
Mass Spectrometry Gas Chromatography Fluorescence 
Spectroscopy 
Nuclear Magnetic 
Spectroscopy 
Ion Mobility 
Spectrometry 
Immunoassay 
Raman Spectroscopy Liquid Chromatography Melting Point 
X-ray Diffractometry Microcrystalline Tests Ultraviolet Spectroscopy 
 Pharmaceutical 
Identifiers 
 
 Thin-Layer 
Chromatography 
 
 
Adulterants 
 Any drug, over the counter or otherwise, can serve as an adulterant.  In 
most circumstances adulterants are present in illicit substances to enhance the 
effect of the illicit drug, thereby increasing its efficacy while decreasing the 
purity (12).  This rationale allows dealers to make more of a profit off of a small 
amount of true product, without their buyers knowing the difference.  In terms 
of cocaine, the adulterants are typically stimulants and anesthetics, in order to 
simulate the euphoric high and the numbing sensation the buyer experiences 
when testing out the product on their lip or skin (8).  Alternatively, some 
depressants such as benzodiazepines and other drug classes are also used in 
cutting cocaine, because of their ability to alleviate some of the more undesirable 
side effects of cocaine use (13).   
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 For many years, agencies and treating physicians have tried to understand 
why specific adulterants are present in street-quality drugs and exactly what 
effects they may have on the user.  This issue is complicated by the differences 
between available drugs across the world.  In Spain, the most commonly 
reported cocaine adulterants are lidocaine, procaine, caffeine, and piracetam (14). 
Piracetam is a dietary supplement prescribed in Europe, Asia, and South 
America but is no longer on the market as such in the United States. In the US it 
is commonly purchased online as a study-aid for college students (15).  A report 
from Italy mentions almost 30 different common adulterants in cocaine, covering 
stimulants, benzodiazepines, amphetamines, over the counter medications, and 
anesthetics (13).  The different options for adulterants vary widely from country 
to country, and even state to state within the US.   
 Each diluent by itself does not seem very harmful at first glance.  
However, many instances have occurred where an additive in street quality 
drugs has caused toxic effects to their user.  In an article in Clinical Pharmacology 
and Therapeutics, a situation is described in which a clot in the blood stream 
travels to the lungs, a phenomenon known as a pulmonary embolism (9). This 
can occur in users who inject a street quality drug sample containing a thick 
powder such as baby powder or baking soda directly into their blood vessels.   
 There have been reports of blood disorders such as methemoglobinemia 
associated with the absorption of benzocaine into the blood stream following 
cocaine use.  Methemoglobinemia is a disorder in which the amount of 
methemoglobin, a form of hemoglobin, is too abundant in the blood (16).  This 
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disorder is dangerous because while hemoglobin can properly release oxygen 
into the blood, methemoglobin cannot.  In a case report submitted to Clinical 
Chemistry, the author references a patient, suffering from apparent cocaine 
overdose, who also suffered from benzocaine-induced methemoglobinemia.  
Upon questioning, the patient submitted his cocaine sample to the hospital, 
which sent it for further testing.  The laboratory used a basic extraction and 
analysis by GC/MS, and benzocaine was confirmed as an adulterant in the 
patient’s cocaine sample (17).  
 In an article from the Journal of the American Medical Association, a case 
report is presented about the symptoms and signs related to lidocaine toxicity.  
Lidocaine does not alter the chemistries of the blood stream like benzocaine; 
rather the additive effects of lidocaine on the central nervous system are what 
make it so dangerous in large amounts.  The effects of lidocaine toxicity are 
similar to any other type of central nervous system depression: sweating, 
euphoria, drowsiness, disorientation, and slowed respirations (18). 
 Adulterants are typically not dangerous alone.  Lidocaine is found in 
topical treatments for sunburns and is sometimes used intravenously as a 
palliative treatment.  Benzocaine is used as an over the counter topical anesthetic 
for oral ulcers, commonly found in products like Orajel ®.  Procaine, more 
recently replaced by lidocaine, is another example of an over the counter 
anesthetic.  The recommended usage for each of these drugs is topical; on the 
surface of the skin or inside the mouth.  While some of the drug can travel 
through the skin and into the bloodstream, the bulk of it remains on the surface 
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of the skin, interacting with the nerves in that layer.  Therefore, not much 
information is available on the actions of these adulterants when they are 
introduced directly into the blood stream through the injection or snorting of 
street quality cocaine. 
 
Levamisole 
 Another dangerous adulterant of recent interest in street-quality cocaine is 
levamisole.  Levamisole is an anti-parasitic in animals and was originally 
approved by the Food and Drug Administration (FDA) in 1991 for concurrent 
use with chemotherapy for cancer treatment.  It was also used to treat 
rheumatoid arthritis, chronic hepatitis B, and other conditions with varied 
results.  In recent years, levamisole-related toxicity has been reported in several 
states in the US and in many cases in Canada.  In each of these cases, the 
circumstances may not be exactly the same, but the patients suffer from generally 
the same set of symptoms and the conclusions made about each of their 
diagnoses is the same.  Because of the actions of levamisole, it can induce a 
condition known as agranulocytosis (19).  Agranulocytosis is a condition in 
which the body lacks the proper number of white blood cells, specifically 
neutrophils, which results in highly suppressed immune function. This condition 
is the reason levamisole was removed from the market in the US in 1999 as an 
FDA approved medication for human consumption (9).  Levamisole is currently 
available as a free base or hydrochloride salt in crystalline white powder, pastes, 
gels, tablets, feed pre-mixes for livestock, and topical or inject-able solutions (20). 
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 In 2011, a group of scientists in Rhode Island performed a medical review 
of comprehensive urine toxicological testing results of patients from several 
hospitals in the area.  The purpose of their review was to determine how often a 
positive result for levamisole occurred.  They narrowed down their criteria to 
patient samples which had tested positive for cocaine.  In 799 screens, 113 patient 
samples were positive for cocaine.  95 of these 113 patient samples contained 
enough information to be suitable for review.  Among these 95 patient samples 
which tested positive for cocaine, 47 were also positive for levamisole and 48 
were not (21).  In a study from Denver, Colorado, 300 samples were obtained and 
tested for cocaine and levamisole over a span of three months in 2010.  Of these 
300 samples, 249 were positive for cocaine, and 194 of those cocaine positive 
samples were positive for levamisole (22).  Each of these studies portrays the 
rapid growth in occurrences of levamisole toxicity related to cocaine use. 
 Levamisole was first reported to be present in cocaine samples by the 
DEA as early as 2003 (22).   In recent years, its prevalence has grown 
tremendously.  In the year 2008, the DEA reported approximately 44.1% of drug 
specimens contained levamisole.  In 2009, this percentage almost doubled to 
73.2% of drug specimens.  In comparison, in Alberta, Canada in 2008, 
approximately 11% of drug specimens were reported to contain levamisole (23).  
Cocaine and heroin samples seized in Luxemburg from the years 2005-2010 were 
analyzed for the presence of adulterants and their concentrations.  This study 
found that of 471 cocaine samples, 246 contained levamisole, but at a mean 
concentration of only 3.3% of the sample analyzed (24).  This range of results 
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from several different parts of the world illustrates the prevalence of levamisole 
in cocaine in recent years, and the increasing possibility of toxicity due to 
ingestion.  In fact, in September 2009, the US Department of Health and Human 
Services Substance Abuse and Mental Health Services Administration issued a 
statement concerning cocaine tainted with levamisole: 
 
“A dangerous substance, levamisole, is showing up with increasing frequency in 
illicit cocaine powder and crack cocaine.  Levamisole can severely reduce the 
number of white blood cells, a problem called agranulocytosis.  This is a very 
serious illness that needs to be treated at a hospital.  If you use cocaine watch out 
for high fever, chills, or weakness, swollen glands, painful sores, any infection 
that won’t go away or gets worse very fast, including sore throat or mouth sores, 
skin infections, abscesses, thrush or pneumonia.” (8) 
  
 Often times, when cocaine is cut or adulterated, the substances utilized are 
simply what is available or what may enhance the product’s effects.  For 
levamisole there are a few ideas as to the reasons for its use as an adulterant in 
cocaine.  The most obvious reason is its availability; levamisole is easily 
obtainable as a veterinary medication and is relatively inexpensive.  Another 
simple, but less likely explanation for the addition of levamisole is the ability of 
its presence to “brand” the cocaine product (9).  Recently, this reason seems to be 
less probable since levamisole is appearing in more and more cocaine (22).  A 
more complex reason arises from recent research into the metabolism of 
  11 
levamisole in horses.  In an article from Analytica Chimica Acta, levamisole has 
been found to produce two active metabolites known as aminorex and rexamino 
in horses (25).  These two substances are structurally similar to some stimulants 
and may help enhance the effects of cocaine in humans. A third theory is that 
levamisole may promote the effects of cocaine pharmacologically through 
inhibition of reuptake of certain neurotransmitters such as catecholamine (26). 
 
Pharmacology 
 Pharmacology is the study of pharmacokinetics and pharmacodynamics 
in order to better understand the movement and elimination of drugs inside of a 
living organism.  These aspects of drugs are very important when considering 
their applications, dosages, side effects, and toxic levels.  When a drug enters a 
human body, the body determines its target site and then how to eliminate it.  In 
order to understand the movement of a drug inside of the human body, it is best 
to start from the administration and follow the drug until it is eliminated.  Drugs 
can be administered in many different ways.  Each route has different effects on 
the body at different rates.  The common methods are listed from fastest to 
slowest in Table 2, however it should be noted that drugs are ultimately 
transported to the liver, regardless of how they were introduced into the body 
(29). 
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Table 2- Common Routes of Administration 
Route of Administration Description 
Inhalation Inhaled in a gaseous form 
 
Intravenous Injected into vessel or under skin/in 
muscle 
Intranasal Inhaled through the nose in a solid 
form 
Transdermal Absorbed into the skin transdermally 
 
Enteral  
(oral, sublingual, rectal) 
Ingested and moves into the 
bloodstream via the stomach and 
intestines 
  
 Once a drug is administered, it either passes through the portal vein and 
into the liver or directly into the rest of the blood stream.  If a drug is provided 
intravenously, it bypasses what is called first-pass metabolism, or metabolism by 
the liver.  This is why intravenous drugs are very effective; they are able to reach 
their destination more quickly and without being metabolized into possibly less 
active compounds.  If a drug is given orally, it must first be absorbed by the 
stomach or intestine, metabolized in the liver, and then distributed into the blood 
stream.  Due to the complexities of drug absorption across lipid membranes, this 
process is considerably more time consuming and can also change the drug into 
less active or completely inactive metabolites (2).    
 The movement of a drug across a lipid membrane is highly dependent on 
the type of transport that is occurring and the dissociation constant of the drug 
that has been administered.  A drug can be absorbed across the lipid membrane 
through passive diffusion, which is the movement of drug from a highly 
concentrated area to that of lower concentration, or active transport, in which the 
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drug is moved across the membrane using a certain amount of energy.  The 
major aspect impacting the movement of a drug across the lipid membrane is the 
dissociation constant of the drug, and its ability to interact with the unique non-
polarity of the lipid membrane.  The dissociation constant, as understood in 
toxicology and pharmacology (pKa) is the pH at which the drug is evenly 
distributed between ionized and non-ionized forms.  This is technically the log of 
the acid dissociation constant, but this form is the utilized form.  Non-ionized 
species can move easily across the membrane, through passive diffusion, while 
ionized species must move by some variant of active transport.  The balance 
between charged and uncharged species is highly dependent on the pH of the 
area of the body that the drug is excreted from.  The stomach is highly acidic; any 
drug that has entered the stomach and has an acidic pKa will exist in its ionized 
form, making the process of crossing the lipid membrane more difficult (2). 
 When a drug is administered intravenously it bypasses this process, but it 
also bypasses the process of first-pass metabolism.  First-pass metabolism is the 
process of the drug being filtered and metabolized by the liver before it reaches 
its target site.  This metabolism can change the drug in such a way that it is less 
effective or completely inactive.  Due to this complication, the preference for 
drug administration is intravenously regardless of whether the drug is 
prescribed or illicit (29).  The effects can be felt sooner, and can permeate the 
tissues more easily.  This administration must be exact due to the consequence 
that once a drug is injected into the blood stream it cannot be removed.  Certain 
requirements for intravenous administration of a drug must also be met in order 
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for the drug to safely enter the blood stream; if the drug is in an oil, or solids are 
present, such as the diluents in cocaine, complications may arise from their 
introduction directly into the blood stream. 
 
Urine Drug Testing 
 Analysis of drugs in biological specimens is used in many fields, 
including forensic and clinical toxicology, hospital testing, pain-care 
management, recovery programs, and workplace drug testing.  Due to the 
somewhat invasive nature of collecting biological specimens, advances are 
always being made to improve upon the analysis by less-invasive collection 
techniques such as oral fluids and hair.  However, the standard for several 
decades has been urine drug testing (27).  Urine testing provides many 
advantages including metabolites and parent drugs that are highly concentrated 
in the sample, a very reliable basis for testing, and high acceptance in both the 
court systems and scientific field.  Although urine is an established means of 
tracking drug intake, it also has several disadvantages.  The most common issues 
with urine drug testing stems from the collection itself; donors are often times 
required to be watched by a collector to prevent tampering with the sample, by 
adulteration or swapping of the sample completely.  While privacy and 
tampering are valid concerns, another more analytical concern is that results 
from urine testing may not correlate with blood testing results (28). 
 Due to the complex matrix that urine presents, it needs to be simplified 
before its contents can be analyzed.  The naturally high salt content of a urine 
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sample can have ion-suppression effects on the drugs and metabolites that are 
being analyzed, making the results inaccurate and the data difficult to obtain.  
Additionally, good laboratory techniques for quantitation of drugs and 
metabolites in urine require the addition of an internal standard to ensure proper 
response ratios.  These tasks are most often accomplished through extraction 
techniques.  These extractions provide a way to “clean-up” and concentrate the 
sample, leaving the biological matrix behind and supplying the analyst with only 
the drugs and metabolites of interest present in the sample.  A sample 
preparation procedure such as an extraction provides the analyst with the 
opportunity to make the analytes of interest more amenable to the analysis he or 
she plans on performing on the sample.  For example, for gas 
chromatography/mass spectrometry (GC/MS), the ideal analyte of interest is 
thermally stable, volatile, and relatively non-polar.  Not all compounds analyzed 
by GC/MS have these attributes, particularly certain drugs and metabolites.  
Therefore, a process known as derivatization can be performed on these 
compounds, in which a chemical is added to the end product of the extraction, 
making the compound better suited for GC/MS analysis. 
 
Calloway Laboratories 
 Calloway Laboratories is a clinical toxicology laboratory located in 
Woburn, Massachusetts.  Calloway Labs provides urine and oral fluid drug 
screening and confirmation for medical practitioners, recovery centers, and 
hospitals across the continental United States (US).  The laboratory is a Clinical 
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Laboratory Improvement Amendments (CLIA), College of American 
Pathologists (CAP), and Joint Commissions (JCO) certified laboratory for drug 
testing.  Calloway’s screening laboratory performs automated enzyme multiplied 
immunoassay technique (EMIT) and enzyme-linked immunosorbant assay 
(ELISA) for screening of drugs in urine and oral fluid samples and also executes 
testing for specific gravity, creatinine and pH of urine samples to investigate the 
presence of any adulterations.  The confirmation laboratory at Calloway 
performs automated and manual extractions of samples followed by analysis by 
GC/MS, liquid chromatography/mass spectrometry/mass spectrometry (LC-
MS/MS) and laser diode thermal desorption/mass spectrometry/mass 
spectrometry (LDTD-MS/MS).  Each sample’s results are reviewed by several 
chemists, checked by an internal certifying officer and, if requested, by an 
external medical review officer.  Calloway Laboratories screens and/or confirms 
for many different types of drugs and metabolites including the following: 
Table 3- Summary of Testing at Calloway Laboratories 
GC/MS LC-MS/MS LDTD-MS/MS 
Barbiturates Amphetamines Buprenorphine 
Heroin Bath Salts Cocaine 
Phencyclidine Benzodiazepines Fentanyl 
Tetrahydrocannabinol Opiates Methadone 
 Synthetic Cannabinoids  
 Tramadol  
 
 The testing demographic at Calloway includes private doctors, pain 
management programs, addiction recovery programs, hospitals and clinics.  Due 
to the wide range of drugs that they test for, Calloway can provide doctors with 
an opinion about a patient’s compliance, if provided with an accurate medication 
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list.  On a daily basis, the confirmation laboratory at Calloway processes and 
releases thousands of patient samples from the entire continental US, with the 
bulk of the testing coming from the opiates, benzodiazepines, and 
buprenorphine samples.   
 
 
 
 
 
 
 
 
 
 
 
 
  18 
Materials 
 Calibrators and quality controls were created using di-ethylaminoethanol 
and para-aminobenzoic acid purchased from Sigma-Aldrich (St, Louis, MO), 
levamisole and lidocaine salts from MP Biomedicals (Solon, OH), HPLC grade 
methanol from J.T. Baker, a Fisher Scientific analytical balance, and glass 
volumetric pipettes and flasks. 
 The experiments were performed using Calloway’s in-house synthetic 
drug free urine, pre-made and validated sodium acetate buffer (100 mM, 
pH=4.5), elution solvent prepared daily consisting of ethyl acetate, isopropanol, 
and ammonium hydroxide from J.T. Baker and EMD Chemicals Inc., pre-made 
reconstitution solvent (10% methanol in DI water), formic acid from J.T. Baker 
and de-ionized water.  The extractions were performed on United Chemical 
Technologies solid-phase extraction columns, utilizing SupelcoTM 24-channel 
extraction manifolds under vacuum, multiple Eppendorf pipettes, glass sample 
test tubes, glass auto-sampler vials and caps, a Beckman Coulter Allegra 6 
Centrifuge, a Scientific Industries Vortex Genie 2, and Caliper Life Sciences 50-
well Turbo-Vaps ®. 
 The samples were analyzed using an Agilent Technologies 1200 series 
Liquid Chromatography (LC) Stack and an Applied Biosystems/MDS Analytical 
API 4000 MS/MS with an electro-spray ionization (ESI) source.  The method 
development utilized a Harvard Technologies infusion pump.  For both the 
method development and the sample analysis, Analyst Software (version 1.5) 
was employed.  Two mobile phases and one wash solution were utilized in the 
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LC analysis.  Mobile phase A consisted of 2% HPLC grade acetonitrile with 0.1% 
formic acid and 2mM ammonium acetate.  Mobile phase B consisted of 0.1% 
formic acid in acetonitrile and the LC wash solution was 30% isopropanol/50% 
acetonitrile/20% DI water by volume. 
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Methods 
Analyte Selection 
 The literature names several common adulterants in cocaine, four were 
chosen based on their popularity and their amenability to an extraction and 
instrumental analysis.  The four analytes chosen were the metabolites of procaine 
and benzocaine, di-ethylaminoethanol (DEAE) and para-aminobenzoic acid 
(PABA), respectively and the compounds lidocaine (LIDO) and levamisole 
(LEVA).   
 
MS/MS Development 
 For mass spectrometry (MS) method development, a 20,000 nanograms 
per milliliter (ng/mL) stock solution was created by placing twenty milligrams 
(mg) of each powdered standard and 226 microliters (µL) of each initially, and 
diluted to one hundred ng/mL.  These neat standards were then diluted as 
necessary to as low as 12.5 ng/mL, depending on their initial response in the MS.  
Each compound was separately loaded onto the instrument using an infusion 
pump and analyzed to determine the proper gas pressures and molecular weight 
targets.  The infusion pump was set to a flow rate of one microliter (µL) per 
minute (min).  This process was completed in the following manner: 
 First, in order to ensure that the proper parent molecule was present, only 
the first quadrupole (Q1) was observed.  During the infusion, the molecular 
weights summarized in Table 4, in grams per mole (g/mol), were analyzed for 
the four compounds: 
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Table 4- Expected Molecular Weights of Compounds 
Compound Expected Molecular 
Weight (g/mol) 
DEAE 117.2 
LIDO 234.3 
LEVA 204.3* 
PABA 137.1 
*Levamisole and Tetramisole are indistinguishable unless separated by chiral 
chromatography.  For the purposes of this study, compounds with this shared molecular 
weight will be identified as levamisole. 
 
 The expected molecular weights were not necessarily the molecular 
weights that were chosen for the analysis.  Due to the transformation of these 
compounds into their respective ions through electrospray ionization (ESI), the 
molecular weights will differ according to their transformation into positive ions.  
The resulting molecular weights in Table 5 were chosen for each analyte. 
Table 5- Q1 Masses 
Compound Observed Molecular 
Ion 
DEAE 118.1 
LIDO 235.2 
LEVA 205.0 
PABA 138.0 
 
 Once the molecular ions for each analyte were determined the gases and 
potentials for each analyte were optimized.  Optimization of each compound is 
necessary due to the large variation of polarity and size of the four compounds 
being analyzed.  While a high gas pressure and high potential may be beneficial 
in fragmenting the larger molecules such as lidocaine and levamisole, it would 
be detrimental to the smaller molecules, di-ethylaminoethanol and para-
aminobenzoic acid. 
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 Using Analyst software, the infusion was continued but the parameters 
were adjusted while observing the general abundance and peak shape of the 
molecule in question.  When a maximum or optimal peak shape and abundance 
was reached, the value for that parameter was noted and entered as the 
permanent parameter.  Figure 1 is an image of the optimization of the collision 
cell exit potential for the fragment ion of di-ethylaminoethanol: 
Figure 1- Optimization of di-ethylaminoethanol fragment, m/z 72.1 
 
This process was repeated for each of the following parameters: 
Gases        Potentials 
Collision activated dissociation (CAD)  De-clustering potential (DP) 
Curtain (CUR)     Entrance potential (EP) 
Gases 1 and 2     Collision energy (CE) 
Ion source (IS)     Collision cell exit potential (CXP) 
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For each table below, gases are in pounds per square inch (PSI) and potentials 
are in volts (V)  
Table 6- Source/Gas Parameters 
Analyte  CAD  CUR  GS1  GS2  IS  TEM DEAE  6  10  35  30  5500  250 LIDO  4  10  35  30  5500  250 LEVA  8  10  35  30  5500  250 PABA  6  10  35  30  5500  250 
TEM is the source temperature, which was altered when the actual LC method was 
implemented, to account for the flow rate, to 750 degrees Celsius. 
 
Table 7- Compound Parameters 
Analyte  DP  EP  CE  CXP DEAE  55  14  23  13.8 LIDO  57  10  24  17 LEVA  57  10  30  17 PABA  57  10  22  16.8 
 
 Some complications were encountered with the abundance levels of para-
aminobenzoic acid.  This particular compound is not stable in the source, causing 
it to break down before it could be properly analyzed.  Due to this instability, 
this particular analyte was acidified with 0.1% formic acid during the infusion to 
improve stability in the ion source.  This additional step has been incorporated 
into the extraction procedure. 
 After the molecular or parent ions had been established, the ions were 
fragmented and their fragments were analyzed and optimized for a multiple 
reaction monitoring  (MRM) method.  The standards were continually loaded 
into the source using the infusion pump, but rather than observing the Q1 cell, 
the collision cell was utilized for fragmentation of the ions.  Several fragments for 
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each ion were observed, but the ion with the highest abundance and the more 
unique molecular weight was chosen for the MRM transitions.  Table 8 
summarizes the results of the collision cell analysis. Table 8‐ Transitions 
Analyte  Molecular 
Ion 
Fragment 
Ion DEAE  118.1  72.1 LIDO  235.2  86.0 LEVA  205.0  178.1 PABA  138.0  94.0 
  
 The molecular weights of the fragments obtained in the collision cell step 
were then entered for the final quadrupole, Q3, and optimized in a similar 
manner to Q1.  It must be recognized that, when using an MRM method, 
although the potentials can vary from compound to compound within a run, the 
gas parameters must remain consistent throughout. Therefore, compromises for 
the gas parameters must be made on all analytes in order to optimize the overall 
analysis.  Given that the optimized results for the gases are virtually the same, 
with the exception of the CAD gas, the gases are still optimized for each 
compound aside from the CAD gas.  The CAD gas was set to 6, to account for all 
four analytes (see Table 5).  
 
LC Method Development 
 To begin the development of the LC method, some basic parameters were 
set before deciding on the gradient and flow rates.  First, the auto-sampler was 
set up with a five-µL injection, with draw and eject speeds of two hundred µL 
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per second.  A needle wash was performed for ten seconds after each sample 
collection, from a wash bottle in the solvent cabinet rather than a wash vial.  The 
column oven was set to twenty-five degrees Celsius to ensure a constant 
temperature.  An Agilent Zorbax Eclipse Plus LC column was utilized.  The 
length of the column was 50 millimeters (mm) with an inner diameter of 4.6 mm.  
This model of LC column is packed with silica beads coated in C18 with a 
particle size of 1.8 micrometers (um). 
 The flow rate is set to 600 µL per minute with a gradient over 5.5 minutes.  
The gradient is summarized in Table 9.  The first three and a half minutes are 
isocratic; 90% A and 10% B.  At 3.50 minutes, the gradient gradually changes to 
10%A and 90% B to elute the compounds off of the column, over the next one 
and a half minutes.  At five minutes the gradient returns to 90% A to prepare the 
column for the next sample. 
Table 9- Pump Parameters 
Time (min) Flow Rate 
(µL/min) 
%A %B 
0.00-3.50 600 90 10 
3.51-4.99 600 10 90 
5.00-5.50 600 90 10 
 
Sample Collection 
 Once the confirmatory testing  results were finalized through the 
Calloway internal system, the samples were set aside for analysis.  The major 
criterion for selecting the samples was the dilution factor that was applied to that 
sample.  Prior to analysis in the confirmation laboratory, each sample is screened.  
Depending on how high the screen is, a dilution factor is applied for the 
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confirmatory analysis.  For the benzoylecgonine assay this dilution factor ranges 
from x1 through x20 or x50.  Due to the large amount of excess urine after the 
larger dilutions are performed and the fact that a large dose of cocaine is 
involved in a large benzoylecgonine result, these specimens were considered to 
be the most suitable for testing during this research.  The larger the dose of 
cocaine that was consumed, the more likely adulterants will be present.  As the 
samples were collected, certain demographic information was collected as well.  
This data included the state from which the sample originated, the volume of the 
remaining sample, and other tests that were performed on that sample for 
possible interferents.  The samples were stored in their original aliquot plastic 
tubes with screw top caps in a refrigerator set to 2-8 degrees Celsius for 
approximately 8-10 weeks prior to analysis. 
 
Linearity 
 A linearity was created for the solid-phase extraction (SPE) development 
and to evaluate the linear range of the instrument.  A stock solution of 20,000 
ng/mL was made using the following: twenty milligrams (mg) each of para-
aminobenzoic acid, lidocaine, and levamisole, and 226 µL of di-
ethylaminoethanol.  The volume of di-ethylaminoethanol was determined using 
the density of this compound, which is 0.884 grams per milliliter (mL).  These 
compounds were placed into a one-liter (L) volumetric flask and methanol was 
added until it reached the line on the flask.  The solution was properly mixed 
until the solids were dissolved. 
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 The following dilutions were made into twenty mL volumetric flasks and 
were made using volumetric pipettes.  Each concentration was diluted in 
methanol to achieve the final volume.  The final result is a thirteen-point curve 
ranging from 7.5-20,000 ng/mL. The linearity was analyzed neat in 10% 
methanol in de-ionized (DI) water with 0.1% formic acid using the 
aforementioned LC/MS/MS method before extraction to ensure validity.  Table 
10 is a summary of the serial dilutions made to create the linearity. 
Table 10- Linearity Dilutions 
Stock #  Final Concentration 
(ng/mL) 
Volume (mL) and Stock Used 1  20,000  20 mg each powder, 226 μL liquid into 1000 mL MeOH 2*  10,000  10 of Stock #1 3*  5,000  10 of Stock #2 4*  2,500  10 of Stock #3 5*  1,500  12 of Stock #4 6*  1,200  16 of Stock #5 7*  600  10 of Stock #6 8*  300  10 of Stock #7 9*  120  8 of Stock #8 10*  60  10 of Stock #9 11*  30  10 of Stock #10 12*  15  10 of Stock #11 13*  7.5  10 of Stock #12 
*These stocks were created in 20mL volumetric flasks; the volume of methanol added to 
each flask is dependent upon the volume of stock placed in it. 
 
Extraction Method 
 Thirteen points on the linearity, including a negative and excluding the 
1500 point, were extracted on three different types of solid phase extraction (SPE) 
column beds, obtained from United Chemical Technologies and labeled as 
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columns A, B and C to evaluate the efficiency of each type of column bed. 
Column A consisted of a co-polymeric bonded phase consisting of octyl- and 
benyl-sulfonic acid, column B was a benzenesulfonic acid phase, and column C 
was a carboxylic acid bed.   
 One mL of synthetic urine was aliquoted into thirty-nine glass test tubes, 
each labeled with the respective concentration to be aliquoted from the linearity.  
100 µL of each point was pipetted into the respective test tube, after which 1mL 
of 100 mM sodium acetate buffer with a pH of 4.5 was aliquoted into each tube.  
The final solutions were mixed on a vortex, spun down in a centrifuge for 10 
minutes at 3500 revolutions per minute to pellet out any solids and allowed to sit 
while the columns were conditioned.  Figure 2 is an image of the Linearity SPE 
set-up for one manifold. 
Figure 2- Linearity Extraction Column Set-up 
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 The SPE columns were labeled with the appropriate concentrations and 
then conditioned first with 2mL of methanol and allowed to move through the 
column bed by gravity only.  Next, 2mL of de-ionized water was dispensed into 
each SPE column and also allowed to move through by gravity only.  Before 
sample addition and after the water finished moving through the column bed, 
one mL of the 100 mM sodium acetate buffer with pH 4.5 was added to each SPE 
column and allowed to move through by gravity. 
 After the columns were conditioned by this method, the samples were 
poured into the respective SPE columns.  The samples were carefully poured 
rather than pipetted to ensure that the solid pellet at the bottom was not added 
to the column.  The samples were allowed to drip through the column beds by 
gravity, and then were washed with two mL of DI water.  Once the water had 
cleared the column beds, the vacuum was turned on and the samples were 
allowed to dry on the beds for approximately ten minutes.   
 While the samples were drying, an elution solvent was made, using ethyl 
acetate, isopropanol, and ammonium hydroxide in a ratio of 90:6:4 by volume, 
respectively.  Once ten minutes had elapsed, a separate set of labeled test tubes 
was placed inside the extraction manifolds, under the respective SPE columns, 
and two mL of elution solvent was added to each column and allowed to drip 
through by gravity, but a small amount of vacuum was applied after most of the 
solvent had moved through, to ensure optimal recovery of the elution solvent. 
 The elution tubes were placed into an automatic turbo evaporator (turbo-
vap) set at forty degrees Celsius, and the samples were dried for approximately 
  30 
thirty minutes.  Once thirty minutes had passed, the tubes were removed from 
the turbo-vap and 2mL of reconstitution solvent, consisting of 10% methanol in 
DI water, was added to each sample and mixed using the vortex.  1mL of each 
sample was aliquoted into an auto-sampler vial, and one µL of formic acid was 
added to each vial. 
 The linearity for each SPE column type was demonstrated using the 
previously developed instrument method.  Once the data was collected, the 
values were calculated using a linear fit through zero, and each of the points was 
set as the expected value until the best fit was obtained.  Some points were left 
out of the best-fit line due to outlier data across all three analytes.  These 
inconsistencies point to an issue with the extraction of that specific point, making 
it suitable for exclusion.  All three SPE column types resulted in no recovery of 
the para-aminobenzoic acid.  The pKa of this particular analyte is low compared 
to the others; it was determined at this time a separate extraction would be 
necessary.  Due to time and supply constraints, this analyte was dropped from 
the remainder of the analysis and the formic acid addition for ionizing the 
resulting extract before instrumental analysis was subsequently removed.  The 
formic acid step in the extraction does not need to be performed without analysis 
of this particular compound; the formic acid step was simply to encourage its 
stability.  The presence of formic acid in the mobile phase A is sufficient for 
ionization of the other compounds in the analysis.   
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Linearity Extraction Results 
SPE Column A- Copolymeric Bonded Phase, octyl- and benzyl-sulfonic acid 
 This SPE column type yielded good results for all three analytes.  The 
linear ranges were the widest on this type of SPE column and the coefficients of 
determination or R2 value were all greater than 0.998, indicating a high level of 
accuracy.   Table 11 contains the linear ranges and R2 values for all three analytes 
evaluated on this column type. 
Table 11- SPE Column A Linearity Results 
Analyte Linear Range (ng/mL) R2 Values 
DEAE 30-600 0.999 
LIDO 300-2500 0.999 
LEVA 30-1200 0.997 
 
Figures 3, 4, and 5 are the best-fit lines for each of the analytes’ linear ranges for 
the Column A Results.  The x-axis represents the target concentration in ng/mL 
and the y-axis represents the actual concentration in ng/mL. 
Figure 3- DEAE Column A Linearity Results 
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Figure 4- LIDO Column A Linearity Results 
 
Figure 5- LEVA Column A Linearity Results 
 
SPE Column B-Benzenesulfonic acid phase 
 This SPE column type yielded better linear results for lidocaine and 
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Table 12- SPE Column B Linearity Results 
Analyte Linear Range (ng/mL)* R2 Values 
DEAE 600 N/A 
LIDO 30-1200 0.994 
LEVA 30-2500 0.988 
*DEAE was within 20% of the expected range for only one point, therefore, it does not 
have a linear range. 
 
Figure 6 and 7 are the best-fit lines for two of the three analytes’ linear ranges for 
Column Type B.  Di-ethylaminoethanol was only within 20% in one point, 600 
ng/mL, therefore no graph is included. 
Figure 6- LIDO Column B Linearity Results 
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Figure 7- LEVA Column B Linearity Results 
 
SPE Column C- Carboxylic acid phase 
 This SPE column type yielded poor results for both di-ethylaminoethanol 
and lidocaine, with linearity only with a few points and very poor R2 values.  The 
linear range and R2 value for levamisole is similar to that for SPE column B.  
Table 13 contains the linear ranges and R2 values for all three analytes evaluated 
on this column type. 
Table 13- SPE Column C Linearity Results 
Analyte Linear Range (ng/mL)* R2 Values 
DEAE 600 N/A 
LIDO 600-1200 0.991 
LEVA 30-2500 0.998 
*DEAE was within 20% of the expected range for only one point, therefore, it does not 
have a linear range. 
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Figures 8 and 9 are the best-fit lines for two of the three analytes’ linear ranges 
for Column Type C.  Di-ethylaminoethanol was only within 20% in one point, 
the 600 ng/mL, therefore no graph is included. 
Figure 8- LIDO Column C Linearity Results 
 
Figure 9- LEVA Column C Linearity Results 
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 Based on the above data, SPE column type A was chosen as the optimal 
column bed for the extraction and evaluation of all three analytes.  While some of 
the linear range will be sacrificed with lidocaine and levamisole, the other two 
column bed types yielded very poor results with di-ethylaminoethanol.  Before 
actual sample extraction was performed, a precision study of quality controls 
and an interference study were performed on the chosen column type to validate 
the method. 
 
Precision 
 Two quality control (QC) standards, 250 and 500 ng/mL respectively, 
were prepared from the 20,000 ng/mL stock solution.  To make up the first QC 
0.5 mL of the stock solution was volumetrically pipetted into a twenty mL 
volumetric flask and then filled with MeOH to the line making a 500 ng/mL 
solution.  Ten mL of this 500 ng/mL solution was volumetrically pipetted into a 
second twenty mL volumetric flask and filled to the line with MeOH creating a 
250 ng/mL solution.  One mL of synthetic urine was placed into twenty-four 
glass extraction tubes.  To the first tube nothing additional was added.  To the 
next three tubes, 100 µL of the following calibrator points were added: 30 ng/mL, 
300 ng/mL and 600 ng/mL.  The QCs of 250 and 500 ng/mL were added to ten 
of the extraction tubes for each level.   
 These twenty-four samples were extracted with the same method as the 
linearity.  These samples were analyzed with the developed instrument method 
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utilized for the linearity evaluation.  Table 14 summarizes the precision for each 
of the three analytes in two QC levels. 
Table 14- Precision Results 
Values 
in 
ng/mL DEAE LIDO LEVA 
Expected 
Value 
Calculated 
Value 
Accuracy 
(%) 
Calculated 
Value 
Accuracy 
(%) 
Calculated 
Value 
Accuracy 
(%) 
267 -6.8 272 -8.8 223 10.8 
297 -18.8 244 2.4 285 -14 
234 6.4 295 -18 238 4.8 
188 24.8 238 4.8 281 -12.4 
291 -16.4 199 20.4 249 0.4 
267 -6.8 288 -15.2 232 7.2 
280 -12 283 -13.2 221 11.6 
226 9.6 263 -5.2 203 18.8 
181 27.6 207 17.2 243 2.8 
250 
244 2.4 190 24 265 -6 
417 16.6 426 14.8 473 5.4 
385 23 428 14.4 453 9.4 
454 9.2 504 -0.8 429 14.2 
463 7.4 499 0.2 471 5.8 
439 12.2 354 29.2 453 9.4 
575 -15 512 -2.4 475 5 
473 5.4 396 20.8 485 3 
433 13.4 497 0.6 470 6 
440 12 438 12.4 408 18.4 
500 
470 6 448 10.4 462 7.6 
 
 Points that fell outside of twenty percent accuracy have been highlighted 
in grey.  Based on the very minimal number of points outside of this range, the 
QCs appear to be of a proper level for the linearities of each of the analytes.   
 
Interference Study 
 In order to study the specificity of the extraction and instrument methods, 
an interference study was performed.  This study consisted of pre-made and pre-
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validated calibrators and QCs from each of the assays performed at Calloway 
Laboratories.  Table 15 is a summary of the analytes and their concentrations 
tested in this study, with the Calibrators/QC’s in ng/mL. 
Table 15- List of Possible Interferents 
Analyte 
 
Conc. 
(ng/mL)  
Analyte Conc. 
(ng/mL) 
6-Acetylmorphine 320 Alprazolam 300 
MDA 250 MDPV 250 
MDEA 250 Mephedrone 250 
Methamphetamine 250 Methylone 250 
MDMA 250 Buprenorphine 100 
Amphetamine 250 n-Buprenorphine 100 
Phentermine 250 Benzoylecgonine 150 
Butalbarbital 250 Fentanyl 250 
Secobarbital 250 n-Fentanyl 250 
Amobarbital 250 JWH 018 5-Hydroxypentyl 0.10 
Pentobarbital 250 JWH 018 N-Pentanoic Acid 0.10 
Butabarbital 250 JWH 073 N-Butanoic Acid 0.10 
Phenobarbital 250 JWH 073 4-Hydroxybutyl 0.10 
Oxazepam 300 Methadone 150 
Nordiazepam 300 EDDP 150 
Temazepam 300 Codeine 300 
Lorazepam 300 Morphine 300 
α-Hydroxyalprazolam 300 Hydrocodone 300 
α-Hydroxytriazolam 300 Hydromorphone 300 
7-Aminoclonazepam 300 Oxycodone 300 
Chlordiazepoxide 300 Oxymorphone 300 
Estazolam 300 PCP 200 
Diazepam 300 THC 100 
2-
Hydroxyethylflurazepam 
300 Tramadol 80 
7-Aminoflunitrazepam 300 n-Desmethyltramadol 80 
  
 Each of these calibrators/QCs was extracted and analyzed using the 
extraction and instrument methods developed.  The results are reported below, 
each table summarizes the results for each analyte individually.  Di-
ethylaminoethanol resulted in some false positive results but the quantitative 
  39 
values are minimal.  The rest of the analytes resulted in trace quantities, resulting 
from noise integration rather than real peaks. 
Table 16- DEAE Interference Study Results 
Analyte Result 
(ng/mL) 
Analyte Result 
(ng/mL) 
6-Acetylmorphine 2.54 Alprazolam 2.10 
MDA 2.84 MDPV 2.26 
MDEA 2.84 Mephedrone 2.26 
Methamphetamine 2.84 Methylone 2.26 
MDMA 2.84 Buprenorphine 41.9 
Amphetamine 2.84 n-Buprenorphine 41.9 
Phentermine 2.84 Benzoylecgonine 32.5 
Butalbarbital 3.07 Fentanyl 39.4 
Secobarbital 3.07 n-Fentanyl 39.4 
Amobarbital 3.07 JWH 018 5-Hydroxypentyl 2.34 
Pentobarbital 3.07 JWH 018 N-Pentanoic Acid 2.34 
Butabarbital 3.07 JWH 073 N-Butanoic Acid 2.34 
Phenobarbital 3.07 JWH 073 4-Hydroxybutyl 2.34 
Oxazepam 2.10 Methadone 24.9 
Nordiazepam 2.10 EDDP 24.9 
Temazepam 2.10 Codeine 34.7 
Lorazepam 2.10 Morphine 34.7 
α-Hydroxyalprazolam 2.10 Hydrocodone 34.7 
α-Hydroxytriazolam 2.10 Hydromorphone 34.7 
7-Aminoclonazepam 2.10 Oxycodone 34.7 
Chlordiazepoxide 2.10 Oxymorphone 34.7 
Estazolam 2.10 PCP 2.35 
Diazepam 2.10 THC 34.3 
2-
Hydroxyethylflurazepam 
2.10 Tramadol 1.45 
7-Aminoflunitrazepam 2.10 n-Desmethyltramadol 1.45 
  
 Lidocaine yielded no positive results for any of the assays with trace 
quantitative values, resulting from noise being manually integrated rather than 
true peaks.  The results for lidocaine are summarized below, with values in 
ng/mL. 
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Table 17- LIDO Interference Study Results 
Analyte Result 
(ng/mL) 
Analyte Result 
(ng/mL) 
6-Acetylmorphine 0.481 Alprazolam 0.274 
MDA 0.293 MDPV 0.250 
MDEA 0.293 Mephedrone 0.250 
Methamphetamine 0.293 Methylone 0.250 
MDMA 0.293 Buprenorphine 0.498 
Amphetamine 0.293 n-Buprenorphine 0.498 
Phentermine 0.293 Benzoylecgonine 0.338 
Butalbarbital 0.295 Fentanyl 1.68 
Secobarbital 0.295 n-Fentanyl 1.68 
Amobarbital 0.295 JWH 018 5-Hydroxypentyl 0.586 
Pentobarbital 0.295 JWH 018 N-Pentanoic Acid 0.586 
Butabarbital 0.295 JWH 073 N-Butanoic Acid 0.586 
Phenobarbital 0.295 JWH 073 4-Hydroxybutyl 0.586 
Oxazepam 0.274 Methadone 0.755 
Nordiazepam 0.274 EDDP 0.755 
Temazepam 0.274 Codeine 0.676 
Lorazepam 0.274 Morphine 0.676 
α-Hydroxyalprazolam 0.274 Hydrocodone 0.676 
α-Hydroxytriazolam 0.274 Hydromorphone 0.676 
7-Aminoclonazepam 0.274 Oxycodone 0.676 
Chlordiazepoxide 0.274 Oxymorphone 0.676 
Estazolam 0.274 PCP 0.337 
Diazepam 0.274 THC 0.550 
2-
Hydroxyethylflurazepam 
0.274 Tramadol 0.245 
7-Aminoflunitrazepam 0.274 n-Desmethyltramadol 0.245 
 
 Levamisole also yielded no positive results for the drugs analyzed.  The 
trace quantitative values resulted only because of noise being integrated rather 
than actual peaks.  The results from levamisole are in the following table, and all 
of the values are in ng/mL. 
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Table 18- LEVA Interference Study Results 
Analyte Result 
(ng/mL) 
Analyte Result 
(ng/mL) 
6-Acetylmorphine 1.20 Alprazolam 0.65 
MDA 0.52 MDPV 7.35 
MDEA 0.52 Mephedrone 7.35 
Methamphetamine 0.52 Methylone 7.35 
MDMA 0.52 Buprenorphine 1.31 
Amphetamine 0.52 n-Buprenorphine 1.31 
Phentermine 0.52 Benzoylecgonine 0.52 
Butalbarbital 1.64 Fentanyl 0.64 
Secobarbital 1.64 n-Fentanyl 0.64 
Amobarbital 1.64 JWH 018 5-Hydroxypentyl 0.54 
Pentobarbital 1.64 JWH 018 N-Pentanoic Acid 0.54 
Butabarbital 1.64 JWH 073 N-Butanoic Acid 0.54 
Phenobarbital 1.64 JWH 073 4-Hydroxybutyl 0.54 
Oxazepam 0.65 Methadone 0.72 
Nordiazepam 0.65 EDDP 0.72 
Temazepam 0.65 Codeine 0.68 
Lorazepam 0.65 Morphine 0.68 
α-Hydroxyalprazolam 0.65 Hydrocodone 0.68 
α-Hydroxytriazolam 0.65 Hydromorphone 0.68 
7-Aminoclonazepam 0.65 Oxycodone 0.68 
Chlordiazepoxide 0.65 Oxymorphone 0.68 
Estazolam 0.65 PCP 0.49 
Diazepam 0.65 THC 0.60 
2-
Hydroxyethylflurazepam 
0.65 Tramadol 0.25 
7-Aminoflunitrazepam 0.65 n-Desmethyltramadol 0.25 
 
 Based on the results of the interference study summarized in Tables 16, 17, 
and 18, the method is conclusively specific for both lidocaine and levamisole but 
appears to show some interference with di-ethylaminoethanol.  The quantitative 
values for these interferences are much less than their expected values, but were 
considered when the actual sample data was evaluated quantitatively.  This 
information was taken into account with the actual sample results from 
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Calloway Laboratories for those drugs and the results obtained in the subsequent 
analysis for di-ethylaminoethanol. 
 
Sample Analysis 
 Before the samples could be extracted, they were arranged into batches, 
each with their own set of calibrators and QCs to ensure proper extraction and 
allow for quantitation of the unknown samples.  Each batch consisted of ninety 
samples or less, with six spots left open for calibrators, QCs and an extracted 
negative, resulting in batches of no more than ninety-six samples.  This batch size 
was selected to account for the availability of 24-channel extraction manifolds 
and available hood space.  Each batch was separately extracted using the 
previously developed extraction method and analyzed with the previously 
developed instrument method.  After the extraction and analysis, the results 
were analyzed to ensure that the calibrators and QCs are within 20% of the target 
values before the sample results were reported.   
 The chromatography for each analyte in each sample was reviewed for 
proper peak shape and sufficient abundance.  The retention time tolerance was 
+/- 0.02 min and the mass tolerance was +/- 0.5 atomic mass units.  The 
following figures are examples of acceptable chromatography, wherein the first 
figure represents the three analyte peaks for the 300 calibrator in batch #1 and 
the second represents the three analyte peaks for a sample from the same batch.   
The peak located on the far left of the image is di-ethylaminoethanol, located in 
the center is lidocaine, and on the far right levamisole.   
  43 
Figure 10- 300 Calibrator Chromatography for Batch #1
 
Figure 11- Sample #47 Chromatography from Batch #1 
 
 Each concentration was calculated by plotting the peak area on a 
calibration curve.  The curve was determined by the calibrators for each batch 
and forced through point 0,0.  Any sample with a concentration above the 
reported limit of quantitation (LOQ) was considered positive.  The LOQ is the 
lowest number which a result can accurately be quantitated; typically ten times 
the signal to noise ratio.  This number is directly related to the sensitivity of the 
instrument and the efficiency of the extraction method.  The values were 
evaluated for carryover based on the carryover observed in the previous 
linearity.  An on column carryover limit (OCCL) was established for each 
analyte, as well as an upper limit of linearity (ULOL).  The OCCL is a value 
  44 
determined by studying the carryover potential of each compound being 
analyzed.  During the LC analysis, each sample is deposited onto the solid-phase 
of the column and eluted later.  If a sample contains a particularly large amount 
of the compound of interest, not all of the molecules will be able to efficiently 
elute from the solid phase, which can lead to carryover.  The ULOL is a value 
determined by the linearity, which defines the highest value that can be 
accurately reported by the method.  These values, in ng/mL, are summarized in 
Table 19. 
Table 19- Assay parameters 
Analyte DEAE LIDO LEVA 
LOQ 30 300 30 
OCCL 2500 2500 10,000 
ULOL 600 2500 1200 
 
 When a value was calculated as above the OCCL, a carryover-check was 
performed on the following sample by re-injecting that sample with a negative 
preceding it, as long as the value was below the ULOL.  The carryover-check 
value was the recorded value. 
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Results/Discussion 
Sample Demographic 
 The analysis included a total of 350 samples.  Due to the testing 
demographic of Calloway Laboratories, 28 states were represented.  The 
following figure is a summary of the number of samples coming from each of the 
represented states, where the x-axis is the postal code for each state, and the y-
axis is the number of samples for that state. 
Figure 12- Sample Count by State 
 
 The majority of the samples came from the northeast and midwest areas, 
with no representation from the northwest and minimal representation from the 
southwest.  For the purposes of this analysis, the following regions were defined. 
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Table 20- Region Definitions 
Region States Region States Region States 
 
 
 
Midwest 
 
IN 
MI 
MO 
OH 
OK 
 
 
Southwest 
 
AZ 
CA 
TX 
 
 
 
 
 
Southeast 
AL 
FL 
GA 
KY 
LA 
MS 
NC 
SC 
TN 
VA 
WV 
 
 
 
 
 
Northeast 
 
 
CT 
ME 
MD 
MA 
NJ 
NY 
PA 
RI 
 
 The majority of the samples came from the midwest and northeast 
regions.  This should not be thought of as a reflection on the demographic of 
cocaine users, rather a demographic of the clients of Calloway Laboratories.  
Figure 13 summarizes the percentages of the samples from each region as 
defined in Table 19.  The largest number of samples originated from the 
Northeast region, with 148 samples (approximately 42%), followed by was the 
Southeast with 123 samples (approximately 35%), the Midwest with 69 samples 
(approximately 20%) and lastly the Southwest with only 10 samples 
(approximately 3%).  
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Figure 13- Sample Count by Region 
 
 
Adulterant Demographic 
 As previously discussed, adulterants in any number of illicit, “street-
quality” drug samples may be different depending on their availability and 
popularity.  This characteristic of cocaine was explored utilizing the results of the 
sample extractions.  For the purposes of this study and to observe any 
developing trends the states were grouped into the aforementioned regions.  The 
first observation was the number of adulterants in each of the samples analyzed.  
The following figure (Figure 14) is a representation of the number of samples 
having any number of the three metabolites tested.  Approximately 60% of the 
samples were positive for only one metabolite, with approximately 32% positive 
for two metabolites, approximately 5% contained all three, and approximately 
3% of the samples tested negative for all three metabolites. 
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Figure 14- Number of Metabolites 
 
 The resulting number of metabolites present may not be an accurate 
representation of all of the adulterants present in the sample for many reasons.  
First, only three metabolites were studied, and there are many types of 
adulterants used in cocaine cutting.  In addition, the collection date of the 
specimen may also be an issue.  Cocaine and its metabolites can remain in the 
system for approximately three days after consumption, which will trigger a 
positive screen and subsequent confirmatory testing.  The compounds of interest 
in this study however, may not be present as long as the primary cocaine 
metabolite benzoylecgonine (BE).  The metabolism of many of these adulterants 
is not properly studied for several reasons; in the case of levamisole, the 
adulterant has been taken off the market for legitimate human medical use and 
in the case of the other compounds, their use is typically topical, rendering 
studies of their intravenous metabolism irrelevant. 
60% 32% 
5% 3% 
Number of Metabolites
One Metabolite
Two Metabolites
Three Metabolites
No Metabolites
  49 
 Certain adulterants are more popular than others in the process of cutting 
cocaine.  One adulterant that has gained more attention over the years and grows 
in popularity each year is levamisole.  In this study, levamisole was found in 340 
of the 350 samples, which is approximately 97% of all of the samples tested.  
Previously conducted studies by the DEA on “street-quality” samples submitted 
to crime laboratories in 2009 revealed that approximately 73% of samples 
contained this dangerous drug, which was a two-fold increase from the year 
before (page 9).  The results of this study show that the utilization of this 
adulterant is still growing. Di-ethylaminoethanol was present in 85 of the 
samples tested, and lidocaine was present in 63 samples, approximately 24% and 
18% of the total sample volume, respectively.  Figure 15 shows the actual number 
of samples positive (y-axis) for each of the metabolites in the population (x-axis). 
Figure 15- Metabolites in Total Population 
  
 The total number of positive samples for each adulterant or adulterant 
metabolite in each region was determined, divided by the total number of 
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samples in that region and multiplied by 100 to give a percentage for each 
adulterant or adulterant metabolite in each region.  The following figure is a 
summary of these percentages with the percentage of samples on the y-axis and 
the region of interest on the x-axis. 
Figure 16- Metabolites by Region 
 
 The popularity of levamisole is shown in all four regions at greater than 
90% each.  This result expresses the increasing utilization of this adulterant in 
cocaine cutting as compared to the data from the aforementioned study in 2011 
in Rhode Island, where approximately half of the samples analyzed contained 
levamisole (21).  Therefore, there is an increased need for awareness about 
levamisole in the clinical world and methods to analyze it in a forensic setting.  
Lidocaine has very consistent results across all regions, appearing in 
approximately 16-20% of the samples in each region.  However di-
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ethylaminoethanol, the metabolite of procaine, is present in all regions but its 
percentages vary from as little as 10% in the Southwest, only one positive sample 
of ten tested from that region, but as large as 48% in the Midwest, testing positive 
in as many as 33 of the 68 samples tested from that region.  This metabolite was 
the only one of the three to show any significant variance in its presence from 
region to region.  It should be noted, however, that this metabolite was also the 
only compound to show any results from the interference study.  The results 
obtained during this analysis raise the question that the MS transition for that 
analyte may not have been specific enough, and perhaps the positive results 
were not di-ethylaminoethanol, but some other compound with a similar 
transition and retention time, within the previously set tolerances of +/- 0.02 
minutes and +/-0.5 atomic mass units.  Perhaps for future work, a more stringent 
tolerance should be required. 
 In an effort to uncover any relation between the concentration of the 
adulterant and the concentration of cocaine in the original drug sample, the 
concentration of levamisole for each sample was plotted against the 
corresponding concentration of benzoylecgonine obtained during confirmatory 
analysis at Calloway Laboratories.  Four scatter plots were created, one for each 
of the regions defined in the sample analysis.  On each of the plots, the x-axis 
consists of the concentration of levamisole in ng/mL and the y-axis is the 
concentration of benzoylecgonine in ng/mL.   
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Figure 17- Levamisole versus Benzoylecgonine Scatter Plots 
 
 No real trends are observed in any of the four regions with this type of 
comparison.  Also, there were a small number of samples from the southwest, 
resulting in a limited view of this particular region. 
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Conclusions 
 In recent years, scientific interest in the adulterants and diluents used in 
cutting “street-quality” illicit drugs has grown.  Law enforcement agencies on the 
federal level have looked into using these substances in samples submitted to 
their laboratories to narrow down the source of the cocaine and eventually track 
down a dealer or distributor.  In addition to this forensic interest, there is a more 
immediate concern in the medical field based on the danger of the adulterants 
and diluents unknowingly placed into the product used by the general 
population.  For these reasons, SPE and LC-MS/MS methods were developed to 
study a few of the metabolites of the more popular adulterants in real urine 
samples. 
 Subsequently, both methods were developed and three of the four chosen 
metabolites and adulterants were successfully analyzed: di-ethylaminoethanol, 
lidocaine and levamisole.  The samples analyzed tested positive for BE, a 
metabolite of cocaine, prior to this study and came from 28 states in the 
continental United States.  The analysis of BE for the samples consisted of 
screening by ELISA followed by solid-phase extraction and subsequent analysis 
on LDTD-MS/MS.  Parameters were determined for the limits of the quantitative 
analysis of the samples by careful validation of the analytical method, including 
but not limited to, sensitivity and precision studies. .  Based on these parameters, 
data was compiled on each of the adulterants and adulterant metabolites and 
observations were made about the meaning of this data compared to the region 
from which the sample originated. 
  54 
 Based on the results, it can be concluded that the popularity of the 
adulterant levamisole is much higher than previous reports mention, due to its 
presence in 97% of the samples analyzed with even distributions across all of the 
regions involved in the analysis.  The adulterant lidocaine appears to have 
consistent representation in all four regions studied but at far less popularity 
than levamisole.  Lastly, the adulterant procaine, with metabolite di-
ethylaminoethanol, appears to be present more prevalently in the midwest than 
any other region but there are some concerns with this analyte due to the results 
of the interference study.  The transition selected for this analyte may not have 
been specific enough.  Due to the lack of specificity, it is likely that other 
metabolites and drugs present in the urine sample resulted in the same transition 
(m/z 118.1 to m/z 72.1) assigned to di-ethylaminoethanol.  The interference 
study results for this particular analyte supports this conclusion. 
 There is no real correlation between the concentrations of levamisole to 
the actual benzoylecgonine in the sample, based on the scatter plots in Figure 17.  
This could be due to a number of factors.  One factor to consider is the timing of 
the actual biological sample collection versus the time since cocaine use.  
Literature shows that the metabolites of cocaine, benzoylecgonine included, may 
be detected in urine for three days after use (29).  But, there is no literature that 
documents the length of detection of levamisole in humans.  The levamisole 
detected in the urine could be from recent use, but could also be a result of 
repeated use.  Also, no information was available as to the dose of the street-
quality cocaine that was ingested.  One other contributing factor to the lack of 
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relationship between these concentrations is related to the ULOL set for both of 
these compounds.  The ULOL for benzoylecgonine in the confirmatory testing 
performed at Calloway Laboratories is 9600 ng/mL and the ULOL of levamisole 
for this method is 1200 ng/mL.  Given that most of the results of the testing are 
outside of the linear range for both of these analytes, the quantitative accuracy at 
this level should be called into question. 
 In conclusion, the results of this study point to consistent representations 
of each adulterant in the four regions tested, except for procaine, which was 
more prevalent in the midwest.  It also raises the awareness of the still-increasing 
popularity of the adulterant levamisole, and the need for more research into why 
this compound is used for cutting cocaine samples and the need for control of its 
sale and distribution.  The results of this research corroborate the results of recent 
studies of actual cocaine samples, but in human biological samples.  This specific 
research coupled with the well-known dangerous effects of levamisole raises the 
concern for the health of the cocaine user significantly and could also be of 
importance in post-mortem considerations.   
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Further Studies 
 The results of this study, while conclusive enough to draw some insights, 
could benefit from many areas of further study.  One area of further research 
includes the need for an internal standard in order to properly quantitate the 
analytes in question and obtain better ratios of the analytes to each other.  The 
linearities of each of the metabolites studied would have improved with a 
corresponding internal standard.  Currently there are no deuterated internal 
standards for di-ethylaminoethanol, para-aminobenzoic acid, levamisole or 
lidocaine available from the large standards suppliers.  In the absence of a 
deuterated internal standard perhaps a substance with a similar retention time 
could be used as a substitute.   
 In addition to the need for internal standards, a method could be 
developed for di-ethylaminoethanol on a different LC column.  During the 
analysis of this analyte using the method developed in this study, the retention 
time was less than one minute, which points to the analyte being almost entirely 
un-retained.  In addition, a better transition could be developed for di-
ethylaminoethanol.  The transition for this analyte was difficult because of its 
small molecular weight and very common functional groups, which does not 
allow for the desired specificity of the transition.  Many laboratories and agencies 
do not have access to an LC-MS/MS due to their cost; therefore, developing a 
GC/MS method could be more helpful for these agencies. 
 Aside from the instrument method, improvements and expansions could 
also be made to the extraction method.  For instance, a different extraction 
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method could be developed to recover the para-aminobenzoic acid, which was 
lost during the SPE method developed in this study.  It is possible a liquid-liquid 
extraction method would be preferred, and one could be developed for this 
particular analyte, allowing for the adjustment of pH to the low pKa for this 
particular compound.   
 Aside from the method improvements, further studies could be 
performed on the sample demographic alone.  A method could be developed for 
other adulterants reported in cocaine samples once information on their 
metabolism was gathered.  Additionally, it was noted that there was an obvious 
lack of samples from the Northwest region of the United States as well as very 
few samples from the Southwest.  This study may have been much more 
encompassing with samples from these two regions or even internationally.  
Lastly, it would be interesting to also look at the metabolites of other common 
adulterants in other illicit drugs such as paracetamol and phenobarbital in heroin 
and dextromethorphan in methylenedioxymethamphetamine (MDMA) (30, 31). 
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